Holen Sie sich die Stockscreener-App
1.97
3.14%
0.06
Inhibikase Therapeutics Inc Aktie (IKT) Neueste Nachrichten
Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Two new hires receive options to buy up to 128,000 Inhibikase shares - Stock Titan
Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Inhibikase advances IKT-001 in pivotal PAH Phase 3 - TipRanks
Inhibikase updates corporate presentation, highlights Phase 3 IKT-001 program and timelines - TradingView
Inhibikase (NASDAQ: IKT) tests PAH pill in pivotal global trial - Stock Titan
IKT News | INHIBIKASE THERAPEUTICS INC (NASDAQ:IKT) - ChartMill
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Inhibikase Therapeutics (IKT) Advances 3% as Shares Test Key Resistance ZoneMFI Overbought - dars.gov.et
Inhibikase Therapeutics (NASDAQ:IKT) Stock Price Down 4.1%What's Next? - MarketBeat
Inhibikase Therapeutics Appoints Deloitte & Touche LLP After Dismissing CohnReznick LLP as Auditor - Kalkine Media
Inhibikase (IKT) Chart: Adds 1.70% to Close at $2.39 in Latest Trading; Trading Range: the Supplied Trading Band Runs From $2.27 to $2.51 for the Current SessionFibonacci Extension - siam.in
Inhibikase (IKT) Chart: Adds 1.70% to Close at $2.39 in Latest Trading; Trading Range: the Supplied Trading Band Runs From $2.27 to $2.51 for the Current SessionDonchian Channel - vinanet.vn
Inhibikase (IKT) Q1 2026 Results: EPS Prints Above Forecast; Post-Earnings: Shares Finish 0.42% Higher at the CloseFree Cash Flow Trends - vinanet.vn
Inhibikase Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Inhibikase Therapeutics (IKT) Slips 1.5% as Shares Test Support at $2.25Shakeout Pattern - vinanet.vn
Inhibikase Loss Widens as Phase 3 PAH Trial Expands - MyChesCo
Inhibikase Therapeutics (IKT) Slips 1.5% as Shares Test Support at $2.25Call Dominated - dars.gov.et
Inhibikase Therapeutics (IKT) Holds Steady at $2.41 as Shares Consolidate Between $2.29 Support and $2.53 ResistanceReversal Setup Alerts - vinanet.vn
IKT Q1 2026 Earnings: Narrower Loss of $0.10 Per Share Beats Estimates as Pre-Revenue Biotech Holds SteadyEPS Surprise History - vinanet.vn
Perceptive group (IKT) discloses 6.9% Inhibikase stake through 10.3M warrant shares - Stock Titan
Nantahala reports 4.30% Inhibikase (IKT) stake across 5.81M shares - Stock Titan
IKT Q1 2026 Earnings: Narrower-than-Expected Loss Despite Modest Share PullbackNegative Surprise Momentum - vinanet.vn
Sands Capital group (NASDAQ: IKT) discloses 9.3% Inhibikase stake plus large warrants - Stock Titan
Inhibikase Therapeutics Faces Rising BIOSECURE, China Supply Chain and Trial Risks That Could Disrupt Growth - TipRanks
Oppenheimer Maintains Inhibikase Therapeutics(IKT.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Inhibikase Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Is Inhibikase Therapeutics Inc (IKT) Positioned for Growth After Reporting $0.11 Loss? GF Score: 36/100 - GuruFocus
LifeSci Capital Maintains Inhibikase Therapeutics(IKT.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Inhibikase grants $2.03 stock options to seven new hires - scanx.trade
Inhibikase Q2 EPS of $(0.11) meets analyst consensus estimates - scanx.trade
Inhibikase Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity - Yahoo Finance
Inhibikase Therapeutics (IKT) Earnings Date and Reports 2026 $IKT - MarketBeat
Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity - GlobeNewswire
Inhibikase Therapeutics, Inc. expected to post a loss of 11 cents a shareEarnings Preview - TradingView
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Perceptive Advisors LLC Sells 3,106,568 Shares of Inhibikase Therapeutics, Inc. $IKT - MarketBeat
Inhibikase Therapeutics (IKT) Declines 4.4% as Stock Pressures Key $2.07 Support ZoneBreadth Thrust - dars.gov.et
Inhibikase Therapeutics (IKT) Slides 4.4% to $2.18 as Biotech Stock Presses Toward Key SupportEarly Entry Signals - vinanet.vn
Inhibikase Therapeutics, Inc. Revenue Breakdown – NASDAQ:IKT - TradingView
Inhibikase Wins FDA Orphan Status for PAH Drug Candidate - MyChesCo
18,030,000-share swap for warrant by Inhibikase Therapeutics, Inc. (IKT) - Stock Titan
H.C. Wainwright reiterates Inhibikase stock rating on FDA orphan drug status - Investing.com Canada
H.C. Wainwright reiterates Inhibikase stock rating on FDA orphan drug status - investing.com
Inhibikase Therapeutics Q1 2026 Earnings: Narrower Loss Beats Estimates as Pipeline Progress Continues - dars.gov.et
IKT Q1 2026 Earnings: Narrower-than-Expected Loss per Share; Shares Slide 4.3%Profit Cycle Analysis - vinanet.vn
Inhibikase Therapeutics (IKT) Slips 1% as Shares Test Key Support at $2.21AI Trade Signals - vinanet.vn
Inhibikase Therapeutics Inc (IKT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Inhibikase Therapeutics Inc (IKT) Cash Flow - TradingKey
1.64%
0.29%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):